Form 4: Nuvalent CEO James Richard Porter Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Nuvalent's CEO, James Richard Porter, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.
Summary
- On October 15, 2024, James Richard Porter, the President and CEO of Nuvalent, Inc., executed a stock option to acquire 27,000 shares of Class A Common Stock at a price of $27.85 per share.
- Simultaneously, Porter sold 26,186 shares at a weighted average price of $102.26, and 814 shares at a weighted average price of $103.01.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on April 2, 2024.
- Following these transactions, Porter directly owns 188,113 shares of Class A Common Stock and holds options for 393,780 shares.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment. There is no information to suggest positive or negative implications for the company's performance.
Future Outlook
The document does not contain specific forward-looking statements, but the ongoing vesting of stock options suggests continued alignment of executive incentives with company performance.
Industry Context
Executive stock option exercises and sales are common in the pharmaceutical industry as part of compensation packages. The use of a 10b5-1 plan indicates a pre-arranged strategy to avoid insider trading concerns.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry often include stock options and restricted stock units to align management's interests with shareholders.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize 10b5-1 trading plans for their executives to manage stock sales in a compliant manner.
- The vesting schedule of the options (four years with monthly installments) is a standard practice in the industry to incentivize long-term commitment.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 01/06/2023 | Start date for vesting of shares underlying the option, vesting over four years in equal monthly installments. |
| 04/02/2024 | Date the reporting person adopted a Rule 10b5-1 trading plan. |
| 10/15/2024 | Date of the transaction involving the exercise of stock options and sale of Class A Common Stock. |
| 01/06/2033 | Expiration date of the stock option. |
| 10/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.